Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail
Sponsor: Reade Rheumatology Research Institute
Listed as NCT04194827, this PHASE4 trial focuses on Rheumatoid Arthritis and remains actively recruiting participants. Sponsored by Reade Rheumatology Research Institute, it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Nov 2022 — Dec 2023 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jan 2020 — Nov 2020 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Reade Rheumatology Research Institute
- Sint Maartenskliniek
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Amsterdam, Netherlands